Trimtech Therapeutics closed a £25 million (US$31 million) oversubscribed seed funding round to advance its targeted protein degradation treatments for neurodegenerative and inflammatory diseases.
Although immune checkpoint inhibitors have shown noticeable clinical benefits, tumor evasion of single-agent immunotherapy occurs in some patients due to the compensatory role of alternative immune checkpoints. A viable strategy could be the use of combination immunotherapies targeting multiple immunosuppressive pathways to fully activate T cells and enhance response rates.
LTZ Therapeutics Inc. has gained IND approval from the FDA for LTZ-301, a first-in-class myeloid engager immunotherapy intended to treat relapsed or refractory non-Hodgkin lymphoma (r/r NHL).
At the recent 2025 congress of the European Crohn’s and Colitis Organisation, researchers from Helixon Therapeutics presented the discovery and preclinical characterization of HXN-1002, a bispecific antibody simultaneously targeting both α4β7 and TL1A that is being investigated as a potential treatment for inflammatory bowel disease.
Researchers from Tianjin University have published data regarding development and preclinical characterization of a new anti-PD-L1/CD40 bispecific antibody (BsAb), BA-4415, designed to activate CD40 signaling specifically in the context of PD-L1 while simultaneously blocking PD-1/PD-L1 signaling.
In autoimmune diseases such as inflammatory bowel disease (IBD), the function of regulatory CD8 T cells (CD8 Treg) is compromised, in part due to the expression of inhibitory KIR receptors (KIR2DL1/2/3) and insufficient inducible T-cell co-stimulator (ICOS) signaling. Mozart Therapeutics Inc. has discovered MTX-201, a new bispecific antibody targeting inhibitory KIR and ICOS that are co-expressed by CD8 Tregs.
Bambusa Therapeutics Inc. has completed an oversubscribed series A financing of approximately $90 million to support its lead programs through phase I trials and advance its pipeline of long-acting bispecific antibodies for immunological and inflammatory disorders.
Akeso Inc. has received IND approval by China’s National Medical Products Administration (NMPA) for AK-139, an IL-4Rα/ST2 bispecific antibody under investigation for a number of indications, including respiratory and skin diseases.
Intercellular communication between tumor cells and cancer-associated fibroblasts (CAFs) plays a key role in tumorigenesis and progression, and CAFs generate an extracellular matrix that provides a repository for factors that promote cancer progression. Alpha Beta Therapeutics Inc. researchers aimed to investigate the mechanisms by which CAFs facilitate tumor initiation and tumorigenesis of pancreatic cancer.
RSS
